Edition:
India

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.71USD
20 Apr 2018
Change (% chg)

$-0.01 (-0.58%)
Prev Close
$1.72
Open
$1.72
Day's High
$1.75
Day's Low
$1.71
Volume
1,516,906
Avg. Vol
1,876,628
52-wk High
$2.75
52-wk Low
$0.73

Select another date:

Thu, Apr 12 2018

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

BRIEF-Novavax Inc Q4 Loss Per Share $0.16

* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Novavax Inc Promotes John Trizzino To CFO Role

* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER

BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018

* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018

BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln

* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:

BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock

* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING‍​ Source text: (http://bit.ly/2Edci1c) Further company coverage:

BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization

* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Novavax reports Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Select another date: